Table 2.
Baseline characteristics, according to recipient total C4 gene copy number
| Characteristic | C4 Gene Copy Number |
Pa | ||
|---|---|---|---|---|
| <4 (n = 513) | 4 (n = 1166) | >4 (n = 290) | ||
| Geographic origin, number (%) | 0.045 | |||
| Europe | 442 (86) | 1049 (90) | 263 (91) | |
| North America | 71 (14) | 117 (10) | 27 (9) | |
| Transplant year (means ± SD) | 1995.9 ± 5.3 | 1996.2 ± 5.2 | 1996.5 ± 5.2 | 0.32 |
| Original renal disease, number (%) | 0.42 | |||
| glomerulonephritis | 190 (37) | 455 (39) | 123 (42) | |
| polycystic kidney disease | 64 (12) | 139 (12) | 37 (13) | |
| diabetes mellitus | 59 (12) | 94 (8) | 24 (8) | |
| Recipient gender, number (%) | 0.34 | |||
| female | 215 (42) | 451 (39) | 108 (37) | |
| male | 298 (58) | 715 (61) | 182 (63) | |
| Recipient age, years (means ± SD) | 46.4 ± 14.1 | 46.8 ± 13.6 | 47.7 ± 13.9 | 0.31 |
| Retransplantation, number (%) | 72 (14) | 152 (13) | 35 (12) | 0.72 |
| Donor gender, number (%) | 0.44 | |||
| female | 203 (40) | 473 (41) | 105 (36) | |
| male | 310 (60) | 692 (59) | 183 (64) | |
| Donor age, years (means ± D) | 39.2 ± 17.1 | 40.9 ± 16.6 | 41.3 ± 15.8 | 0.18 |
| Cold-ischemia time, hours (means ± SD) | 20.7 ± 8.2 | 20.2 ± 8.4 | 20.0 ± 7.8 | 0.39 |
| HLA mismatch (A, B, DR), number (%) | <0.001 | |||
| 0 to 1 | 94 (18) | 116 (10) | 23 (8) | |
| 2 to 4 | 361 (70) | 882 (76) | 216 (74) | |
| 5 to 6 | 58 (11) | 168 (14) | 51 (18) | |
| Recipients typed HLA-A1, -B8, and -DR3, number (%)b | 202 (39) | 26 (2) | 1 (0) | <0.001 |
| Panel-reactive antibody, number (%) | 0.89 | |||
| 0 to 5% | 312 (65) | 706 (65) | 179 (67) | |
| 6 to 50% | 87 (18) | 214 (20) | 51 (19) | |
| >50% | 79 (17) | 169 (15) | 38 (14) | |
| Initial immunosuppression, number (%) | 0.7 | |||
| CsA + AZA + steroids | 204 (40) | 475 (41) | 120 (41) | |
| CsA + MPA + steroids | 99 (19) | 223 (19) | 46 (16) | |
| CsA + steroids | 90 (18) | 189 (16) | 44 (15) | |
| Tac + MPA + steroids | 57 (11) | 113 (10) | 35 (12) | |
| otherc | 63 (12) | 166 (14) | 45 (16) | |
| Induction antibody therapy, number (%) | 0.83 | |||
| IL-2 receptor antibody | 48 (9) | 101 (9) | 21 (7) | |
| depleting antibody | 133 (26) | 292 (25) | 71 (24) | |
AZA, azathioprine; CsA, cyclosporin A; MPA, mycophenolic acid; Tac, tacrolimus.
aP values are given for comparisons among all three groups.
bHLA antigens corresponding to the 8.1 ancestral haplotype.
cThe rate of each other combination is less than 3%.